{
  "pmcid": "11419452",
  "sha256": "95c5fd0575fea3ec6970e4c8226853b960e03e8d68dc8d06bd2b5b13df7c9764",
  "timestamp_utc": "2025-11-09T23:15:56.179366+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 10.112818825910932,
    "reading_ease": 40.889363191632924,
    "word_count": 247
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Balloon Dilation vs. Hydrostatic Dilation for Arteriovenous Fistula in Chronic Renal Failure Patients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "patients with cephalic vein diameters <2 mm were randomly assigned to BD or HD groups"
      },
      "Participants": {
        "score": 2,
        "evidence": "patients with cephalic vein diameters <2 mm were randomly assigned to BD or HD groups. Conducted at Shanxi Bethune Hospital"
      },
      "Intervention": {
        "score": 2,
        "evidence": "balloon dilation (BD) compared to hydrostatic dilation (HD)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This randomised controlled trial evaluated the effectiveness of balloon dilation (BD) compared to hydrostatic dilation (HD)"
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the 1-year primary patency rate"
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was performed using a computer-generated sequence, and allocation was concealed with sealed envelopes"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not applied"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Forty-two patients were randomised: 22 to BD and 20 to HD, recruited from August 1, 2018, to September 1, 2021"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Analysis was per-protocol"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The 1-year primary patency rate was 61.9% for BD and 11.1% for HD (p = 0.045)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No adverse events were reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not provided"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 18,
    "max_score": 25
  }
}